Creo Medical Group (LON:CREO) Posts Quarterly Earnings Results

Creo Medical Group (LON:CREO) issued its quarterly earnings results on Friday. The company reported GBX (0.04) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 600 million during the quarter. Creo Medical Group had a net margin of 768.18% and a return on equity of 32.72%.

Creo Medical Group Stock Up 27.5%

CREO stock opened at GBX 14.50 on Friday. Creo Medical Group has a twelve month low of GBX 9.52 and a twelve month high of GBX 18.50. The company has a market cap of £59.81 million, a PE ratio of -14.50 and a beta of 1.62. The business’s 50-day simple moving average is GBX 12.09 and its 200 day simple moving average is GBX 12.18. The company has a quick ratio of 2.19, a current ratio of 5.28 and a debt-to-equity ratio of 6.90.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Creo Medical Group in a research report on Thursday, April 16th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.